1 option
Principles of Immunotherapy in Breast and Gastrointestinal Cancers : Activity, Mechanisms of Resistance and New Sensitization Strategies / Michele Ghidini, editor.
- Format:
- Book
- Series:
- Breaking tolerance to anti-cancer cell-mediated immunotherapy.
- Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy Series
- Language:
- English
- Subjects (All):
- Stomach--Cancer.
- Stomach.
- Digestive organs--Cancer.
- Digestive organs.
- Physical Description:
- 1 online resource (206 pages)
- Edition:
- First edition.
- Place of Publication:
- London, England : Academic Press, [2025]
- Summary:
- Principles of Immunotherapy in Breast and Gastrointestinal Cancers: Activity, Mechanisms of Resistance and New Sensitization Strategies presents updated research findings on immunotherapy, with special focus on the mechanisms of resistance of those cancer types and how to overcome them.The book discusses topics such as tumor cell-intrinsic and.
- Contents:
- Intro
- Principles of Immunotherapy in Breast and Gastrointestinal Cancers: Activity, Mechanisms of Resistance and New Sensitizat...
- Copyright
- Cover Image Insert
- Aims and Scope of Series ``Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy´´
- About the Series Editor
- Aims and scope of the volume
- About the Volume Editor
- Preface
- Contents
- Contributors
- Chapter 1: Mechanisms of resistance to immunotherapy
- Introduction
- The immune system
- The innate immune system
- The adaptive immune system
- How does the immune system control cancer?
- Immunosurveillance
- Immunity cycle
- Historic achievements in immunotherapy
- Overview of immunogenic approaches
- Monoclonal antibodies
- Monoclonal antibodies against tumor antigens
- Monoclonal antibodies against checkpoint molecules
- Antibody drug conjugates
- Nonspecific immunotherapies
- Oncolytic virus therapies
- T-cell therapy
- Cancer vaccines
- Rational of combination treatments
- Resistance factors
- Primary, adaptive, and acquired resistance
- Mechanisms of resistance to immunotherapy
- Tumor cell intrinsic resistance to immunotherapy
- Alterations in antitumor immune response pathways
- Aberrant tumor antigen expression and absence of antigenic proteins
- Antigen presentation pathways
- Alterations in signaling pathways within tumor cells
- Interference with IFNγ signaling pathway
- Aberrant Wnt/β-catenin signaling
- Changes in EGFR, RAS, and MAPK signaling
- (Secreted) Immunosuppressive molecules
- Tumor cell extrinsic resistance to immunotherapy
- Immunosuppressive cells and molecules
- T cells
- MDSCs
- TAMs
- T-cell dysfunction
- Metabolic shifts in tumor cells affecting the TME
- Abnormal neovascularization
- Host-related factors
- The gut microbiome
- Gut microbiota and the intestinal mucosal immune system.
- The modulatory effect of gut microbiome on cancer immunotherapies
- Age, biological sex, and obesity
- Conclusion
- References
- Chapter 2: Biomarker-based immunotherapy in breast cancer
- Predictive biomarkers for tailoring patient selection
- PD-L1
- Harmonization of the diagnostic strategies for the PD-L1 assessment
- Rationale for PD-L1 assessment based on SP142 and 22C3 assays
- Challenges and overcoming strategies
- Mismatch repair and microsatellite instability
- Conclusions
- Acknowledgments
- Chapter 3: Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resis
- The immune system in BC
- Immune elimination, equilibrium, and escape
- Tumor-infiltrating lymphocytes
- Immunogenic properties of BC
- Immunotherapy of BC
- Immunotherapy in triple-negative BC
- Immunotherapy in HER2+ BCs
- Immunotherapy in HR+ BCs
- Immunotherapy in BRCA (BC gene)-mutated BC
- Patterns of clinical response to immunotherapy
- Biomarkers of response to immunotherapy
- Tumor-associated features that can predict cancer antigenicity
- Immune system-related predictors of benefit from immunotherapy
- Novel approaches
- Resistance to immunotherapy
- Cancer cell-intrinsic mechanisms of resistance: The presentation of the antigen
- Cancer cell-intrinsic mechanisms of resistance: The oncogenic activation of various signaling pathways
- Cancer cell-extrinsic mechanisms of resistance: Immunosuppressive TME and exhausted T cells
- Cancer cell-extrinsic mechanisms of resistance: Characteristics of the host
- Strategies to overcome immunoresistance
- Increasing tumor immunogenicity and T-cell priming
- Overcoming T-cell exhaustion
- Improving tumor immune microenvironment
- Combination with target therapy
- Epigenetic modulation.
- Enhancing tumor infiltration by T cells
- Microbiome
- Future perspectives
- Chapter 4: Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers
- Gastroesophageal cancer
- MMR/MSI
- EBV
- TMB
- Other biomarkers for combinatorial therapies with ICIs
- Her2
- CLDN18.2
- Small bowel and colorectal cancer
- Anal cancer
- TILs
- Biliopancreatic cancers
- Gastroenteropancreatic neuroendocrine neoplasms
- Chapter 5: Immunotherapeutic strategies in hepatopancreatobiliary cancers
- Hepatocellular carcinoma
- MSI status
- Gene mutations
- Gut microbiome
- Pancreatic cancer
- Predictive immune biomarkers
- Looking for the holy grail of PDAC immunotherapy
- Biliary tract cancer (BTC)
- Tumor-immune microenvironment of BTC
- Immune checkpoint inhibitors in BTC management
- Predictive biomarkers
- Perspectives on how to increase the success of immunotherapy in BTC
- Chapter 6: Immunotherapeutic strategies for the treatment of colorectal cancer
- ICIs in dMMR/MSI-H mCRC
- Rationale for the use of ICIs in dMMR/MSI-H mCRC
- Approved treatments and ongoing studies in dMMR/MSI-H mCRC
- Mechanisms of primary and secondary resistance to ICIs in dMMR/MSI-H mCRC patients
- MSI testing and radiological assessment
- Site of metastatic disease
- Immune-related molecular biomarkers
- ICIs in MSS mCRC
- The challenge of ICIs in MSS mCRC
- How to overcome primary and secondary resistance to ICI in MSS and MSI mCRC
- Combination of ICIs, antiangiogenic agents, with or without chemotherapy.
- Combination of ICIs, tyrosine kinase inhibitors, with or without chemotherapy
- Rationale and clinical trials of ICI combination with anti-EGFR antibodies
- Rationale and clinical trials of PD1/PD-L1 with or without CTLA4 and LAG3 ICI
- Adoptive cell transfer therapy (ACT) and tumor vaccines
- Immunotherapy in early colorectal cancer
- Neoadjuvant therapy for MSI/dMMR tumors
- Adjuvant therapy for MSI/dMMR tumors
- Immunotherapy for localized tumors beyond MSI/dMMR
- Predictive factors of response to immunotherapy in colorectal cancer and biomarkers for patients selection
- Tumor mutational burden and PD-L1 expression
- Tumor-infiltrating lymphocytes, immunoscore
- POLE, consensus molecular subtype and other gene signatures
- Chapter 7: Immunotherapeutic strategies in gastroesophageal tumors
- The role of immunotherapy in early-stage GEC
- Immunotherapy for advanced GEC
- Esophageal squamous cell carcinoma
- First-line treatment
- Second and further lines of treatment
- Esophageal, gastric, and GEJ adenocarcinoma
- Later lines of treatment
- Mechanisms of resistance and further perspectives
- Chapter 8: Concluding remarks and future perspectives
- Index.
- Notes:
- Includes bibliographical references and index.
- Description based on publisher supplied metadata and other sources.
- Description based on print version record.
- Other Format:
- Print version: Ghidini, Michele Principles of Immunotherapy in Breast and Gastrointestinal Cancers
- ISBN:
- 9780443133756
- OCLC:
- 1453198802
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.